Oddity Tech Ltd. Q3 2026 Earnings Call Summary Moby Intelligence Wed, November 11, 2026 at 5:00 PM EST 4 min read NVDA -0.55% ODD +2.03% Explore stocks on Coinbase Trading disclosure Trading disclosure The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for certain activity generated through this link. Prices displayed are informational.
Our analysts just identified a stock with the potential to be the next Nvidia. Tell us how you invest and we'll show you why it's our #1 pick. Tap here.
Management attributes the Q3 performance beat to the continued scaling of SpoiledChild and the successful launch of METHODIQ, which offset ongoing technical headwinds at IL MAKIAGE.
The 'ODDITY platform' is being positioned as a repeatable brand-building machine, evidenced by SpoiledChild reaching a $350 million revenue run rate in less than five years without M&A.
A significant 'algorithm dislocation' with the company's largest advertising partner remains the primary driver of IL MAKIAGE's first-order revenue decline, which management is addressing through 24/7 technical collaboration.
The business model is shifting toward a high-margin repeat base, with over 80% of Q3 net revenue coming from repeat sales, providing stability while customer acquisition channels are recalibrated.
Strategic expansion into medical-grade wellness via METHODIQ is designed to capture secular demand for high-efficacy products in dermatology and longevity.
ODDITY Labs is being utilized as a competitive moat, applying pharmaceutical-grade discovery tools to develop proprietary molecules for anti-aging and hair growth.
Management is leveraging a strong liquidity position to aggressively reduce share count, repurchasing approximately 20% of ordinary shares year-to-date.
Management's primary objective for 2027 is returning all brands, including IL MAKIAGE, to growth supported by what they describe as their most exciting product launch slate to date.
METHODIQ plans to expand into the longevity and metabolic health markets by offering prescription injectable therapies, including NAD+ and Sermorelin, through existing pharmacy infrastructure.
The launch of 'Brand 4' is scheduled for 2027, which management expects will further validate the platform's ability to scale multiple billion-dollar brands simultaneously.
Management expects that returning the business to growth in 2027 will require a necessary step-up in investment for first-order customer acquisition to restart the growth flywheel., though management maintains a strict 12-month profitability requirement for all spend.
The company expects to resolve IL MAKIAGE's excess inventory position by 2027 as revenue trends normalize and purchase commitments are better aligned with demand.
The IL MAKIAGE advertising account dislocation continues to cause volatility in return on ad spend and has led to a sharp decline in first-order revenue.
Gross margin compression to 67.4% was primarily driven by a mid-single-digit decline in Average Order Value (AOV) resulting from a higher mix of repeat orders versus first orders.
Inventory levels remain elevated at $158 million, specifically within IL MAKIAGE, due to prior purchase commitments made before the advertising dislocation occurred.
The company maintains a significant $561 million cash cushion and $350 million in undrawn credit to fund future growth initiatives and opportunistic capital management.
One stock. Nvidia-level potential. 30M+ investors trust Moby to find it first. Get the pick. Tap here.
Management believes their existing telehealth and pharmacy infrastructure, built for dermatology, allows for a low-friction expansion into the peptide category.
The recent HHS enforcement discretion policy change is viewed as a major catalyst for METHODIQ to capture early-mover advantage in metabolic health.
Success in this category will rely on the platform's ability to establish consumer confidence through high-quality medical partnerships.
CEO Oran Holtzman is personally dedicating 40% to 60% of his time to working with the advertising partner to iterate on the algorithm.
The recovery strategy involves a combination of technical account resets and launching new products to help the algorithm 're-learn' the target customer profile.
Management noted that while September showed the best CPA trends of the year, the environment remains highly volatile.
Returning to growth will require higher upfront acquisition costs, but management will only deploy capital where 12-month profitability is clear.
The company is prepared to 'bury losers quickly' if new category expansions do not meet strict internal return thresholds.
Repeat order stability in Q3 provides the financial flexibility to fund these aggressive first-order acquisition efforts in 2027.
